Investors have long enjoyed a love-hate relationship with pharmaceutical stocks. This sector is unique in that their products are effectively scheduled for obsolescence via expiring patents. As such, a pharmaceutical company's pipeline of new products is just as important, or maybe more important, than the company's current offerings. Let's play the part of Goldilocks and take a look at three leading pharmaceutical stocks and see how they stack up as potential dividend income investments: